Literature DB >> 24378281

Walking and cognition, but not symptoms, correlate with dual task cost of walking in multiple sclerosis.

Robert W Motl1, Jacob J Sosnoff2, Deirdre Dlugonski2, Lara A Pilutti2, Rachel Klaren2, Brian M Sandroff2.   

Abstract

BACKGROUND: Performing a cognitive task while walking results in a reduction of walking performance among persons with MS. To date, very little is known about correlates of this dual task cost (DTC) of walking in MS.
PURPOSE: We examined walking performance, cognitive processing speed, and symptoms of fatigue, depression, anxiety, and pain as correlates of DTC of walking in MS.
METHODS: 82 persons with MS undertook a 6-min walk test (6MWT) and completed the Symbol Digit Modalities Test (SDMT), Fatigue Severity Scale (FSS), Short-form of the McGill Pain Questionnaire (SF-MPQ), Hospital Anxiety and Depression Scale (HADS), and self-reported Expanded Disability Status Scale (SR-EDSS). The participants completed 4 trials of walking at a self-selected pace on an electronic walkway that recorded spatiotemporal parameters of gait. The first 2 trials were performed without a cognitive task, whereas the second 2 trials were completed while performing a modified Word List Generation task.
RESULTS: There were significant and large declines in gait performance with the addition of a cognitive task for velocity (p<.001, η2=.52), cadence (p<.001, η2=.49), and step length (p<.001, η2=.23). 6MWT and SDMT scores correlated with DTC for velocity (r=-.41, p<.001 and r=-.32, p<.001, respectively) and step length (r=-.45, p<.001 and r=-.37, p<.001, respectively); there were no significant associations between FSS, SF-MPQ, and HADS scores with the DTC of walking. Regression analyses indicated that 6MW, but not SDMT, explained variance in DTC for velocity (ΔR2=.11, p<.001) and step length (ΔR2=.13, p<.001), after controlling for SR-EDSS scores.
CONCLUSION: Walking performance might be a target of interventions for reducing the DTC of walking in MS.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cognition; Fatigue; Gait; Multiple sclerosis; Walking

Mesh:

Year:  2013        PMID: 24378281     DOI: 10.1016/j.gaitpost.2013.11.023

Source DB:  PubMed          Journal:  Gait Posture        ISSN: 0966-6362            Impact factor:   2.840


  6 in total

1.  Backward Walking and Dual-Task Assessment Improve Identification of Gait Impairments and Fall Risk in Individuals with MS.

Authors:  Erin M Edwards; Deborah A Kegelmeyer; Anne D Kloos; Manon Nitta; Danya Raza; Deborah S Nichols-Larsen; Nora E Fritz
Journal:  Mult Scler Int       Date:  2020-09-08

2.  The association between cognition and motor performance is beyond structural damage in relapsing-remitting multiple sclerosis.

Authors:  Damiano Mistri; Laura Cacciaguerra; Loredana Storelli; Alessandro Meani; Claudio Cordani; Maria A Rocca; Massimo Filippi
Journal:  J Neurol       Date:  2022-03-12       Impact factor: 6.682

Review 3.  Cognitive-motor interference in multiple sclerosis: a systematic review of evidence, correlates, and consequences.

Authors:  Douglas A Wajda; Jacob J Sosnoff
Journal:  Biomed Res Int       Date:  2015-03-09       Impact factor: 3.411

4.  Comparing Three Dual-Task Methods and the Relationship to Physical and Cognitive Impairment in People with Multiple Sclerosis and Controls.

Authors:  Megan C Kirkland; Elizabeth M Wallack; Samantha N Rancourt; Michelle Ploughman
Journal:  Mult Scler Int       Date:  2015-11-23

5.  Frontal brain activation changes due to dual-tasking under partial body weight support conditions in older adults with multiple sclerosis.

Authors:  Gioella Chaparro; Julia M Balto; Brian M Sandroff; Roee Holtzer; Meltem Izzetoglu; Robert W Motl; Manuel E Hernandez
Journal:  J Neuroeng Rehabil       Date:  2017-06-29       Impact factor: 4.262

6.  The effect of prioritization over cognitive-motor interference in people with relapsing-remitting multiple sclerosis and healthy controls.

Authors:  Barbara Postigo-Alonso; Alejandro Galvao-Carmona; Cristina Conde-Gavilán; Ana Jover; Silvia Molina; María A Peña-Toledo; Roberto Valverde-Moyano; Eduardo Agüera
Journal:  PLoS One       Date:  2019-12-23       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.